Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential.

The importance of this for public health is often overlooked in favor of “sexier” areas of medicine, like immuno-oncology or gene therapy. Investor interest is drawn here because of the cutting-edge science and promise of game-changing therapies. However, investors downplay the fact that these programs can be many years away from approval and have a significant chance of clinical failure...